Navigation Links
Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
Date:12/17/2008

EMERYVILLE, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that an independent Data Safety Monitoring Board (DSMB) has determined that the current clinical trials of Viprinex(TM) for the treatment of acute ischemic stroke are unlikely to show benefit. As a result, the company has terminated further enrollment in the trials. NTI will obtain and analyze the data before evaluating the potential for any future development of Viprinex. The interim analysis conducted by the DSMB evaluated stroke patients' outcome 90 days following an acute ischemic stroke, comparing treatment with Viprinex to treatment with placebo. The DSMB determined that there was no clinically meaningful difference in outcome between the two treatment groups as measured on the modified Rankin scale of disability, the primary endpoint of the study.

"We are deeply disappointed that Viprinex did not improve overall patient outcomes in our clinical study," said Paul E. Freiman, president and chief executive officer. "This news is a significant set-back for our clinical program. Once we obtain the data and we have analyzed the results from this study, which we expect to occur in early 2009, we will determine whether we will pursue any further development of Viprinex. In the meantime, we are implementing plans we have developed to reduce our expenses, which will likely result in a significant reduction in our overall headcount if we determine that future development of Viprinex is not warranted."

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
2. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
3. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
4. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
5. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
6. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
7. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
8. ImmunoVaccine Technologies DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
9. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
10. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
11. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Hill-Rom Holdings, Inc. ... to a management presentation at the Morgan Stanley Global ... EDT. You are invited to listen to ... http://ir.hill-rom.com/events.cfm or access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP ... available one hour after conclusion of the live event ...
(Date:8/27/2014)... DANVERS, Mass. , Aug. 27, 2014 North ... with a prestigious R&D 100 Award for the new OSRAM ... laser and LED-based white light module for microscopy, endoscopy and ... Xenon lamps with significantly higher efficacy and lamp life. ... as one of the most innovative new technologies of ...
(Date:8/27/2014)... Aug. 27, 2014 Amgen (NASDAQ: ... Administration (FDA) has granted priority review designation for ivabradine ... is an oral drug that inhibits the I ... node, the body,s cardiac pacemaker. 1 Ivabradine works ... myocardial contractility or ventricular repolarization. 1 Heart failure ...
Breaking Medicine Technology:OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7
... First U.S. Clinical Data on XIENCE V ... Follow-Up,Results from the ABSORB Bioabsorbable Stent Clinical ... /PRNewswire-FirstCall/ --,Abbott will present data from several ... during a number of late-breaking,clinical trial and ...
... La Jolla,Pharmaceutical Company today announced updated interim antibody,reduction ... (abetimus,sodium), its drug candidate for systemic lupus erythematosus,("lupus" ... that there is a definitive and significant dose ... mg doses of Riquent compared,with placebo (p=0.0001). These ...
Cached Medicine Technology:Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 2Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 3Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 4Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6
(Date:8/28/2014)... 28, 2014 The next episode of ... from Tallahassee, Fla. He’s a drama coach who longs ... frame has made achieving that dream impossible. , Featuring ... Weight Loss” airs Tuesday, September 2 (9:00-11:00 p.m., ET/PT) ... wears a big smile on the outside to hide ...
(Date:8/27/2014)... The report provides market analysis of “Military ... Finder, LIDAR, 3D scanner, Laser Weapon, Dazzlers, Laser sights, ... Altimeter) by Domain (Aerospace, Defense and Homeland Security) - ... MarketsandMarkets, and its application in the aerospace and defense ... Systems market is expected to register a CAGR of ...
(Date:8/27/2014)... FL (PRWEB) August 27, 2014 ... money-saving dental plans, has launched in the state ... access to quality, affordable dental care services at ... destination for Tennessee consumers looking to save money ... dental rates as a member of discount fee ...
(Date:8/27/2014)... National Resident Matching Program International ... Medical Education in Europe (AMEE) Conference being held at ... – September 3, 2014. As an exhibitor, NRMPI ... community, share the benefits of its matching services, and ... in countries throughout the world. , “Exhibiting ...
(Date:8/27/2014)... Arrow, OK (PRWEB) August 27, 2014 When ... their guests a comfortable bed to sleep without breaking the ... the market for a new foam mattress set for the ... to sleep on, Bedding Mart has it all during their ... stock up on some of the best mattresses for the ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Rod’s Journey Begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 4Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 2Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 3Health News:National Resident Matching Program International (NRMPI) to Exhibit at the 2014 AMEE Conference 2Health News:Bedding Mart, Top Mattress Store in Broken Arrow Oklahoma, Announces a Huge Labor Day Sale 2
... accident, skull separating from her spine, has survived to tell ... ,A car crash slammed her into the dashboard. Her ... and other internal organs remained intact. The rare condition is ... no control over her head. ,Surgeons said her ...
... Since it is a very painful process, continuous attempts are ... the patient. ,Now researchers say that LHRH agonists ... the production of a female hormone that encourages some tumours ... often mimicking the action of a naturally occurring substance. ...
... affects to work, sleep and performance of other activities but ... and your concentration. ,This is the finding ... Rashiq at the University of Alberta. ,As a ... Pain Centre in Edmonton, Canada, the researchers studied 24 patients, ...
... a type of kidney malignancy called renal cancer according to ... Women's Hospital in Boston found that women and men who ... about 30 percent less likely to develop renal cell cancer ... drank beer, wine or liquor. ,Jung Eun Lee ...
... addition of folic acid to flour or bread mandatory in order ... ,After lengthy public consultations the Food Standards Agency (FSA) ... next month after it decides whether folic acid should be added ... the FSA's proposals, it will be the first time since the ...
... of Psychiatric and Mental Health Nursing in a recent report, ... health support to the victims of the 2005 Bali ... first explosions in 2002. ,Staff at the Royal ... recipients of vital personal support from mental health nurses. ...
Cached Medicine News:Health News:30-year-old Woman Survives 'internal Decapitation' 2Health News:A Fresh Alternative to Painful Chemotherapy Developed in UK 2Health News:Chronic Pain can Impair Memory and Concentration 2Health News:UK too Will Insist on Folic Acid in Bread 2Health News:UK too Will Insist on Folic Acid in Bread 3Health News:Bali Bombings Helped Improve Trauma Care 2Health News:Bali Bombings Helped Improve Trauma Care 3
The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s...
This chamber is designed to provide a large workspace and gloveless dexterity in closed environment industrial, research and development, quality control packaging applications. Atmospheres of nitrog...
... incorporates all the familiar and proven features of ... with the Ruskinn patented gas mixing system.The gas ... - 20% in 0.1% increments), carbon dioxide (0% ... - 10% in 1% increments) components of the ...
... anaerobic workstation shares the innovative ... Concept systems.Bugbox is the perfect ... and is an easy to ... Bugbox is perfect as a ...
Medicine Products: